Marcus Gutmann

Dr. Marcus Gutmann

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
MBMatthias Beudert
Matthias Beudert
MGMarcus Gutmann
Marcus Gutmann
TLTessa Lühmann
Tessa Lühmann
LMLorenz Meinel
Lorenz Meinel

27 May 2022 in Chemistry – A European Journal
Verified
Journal Article
Open access
JHJulian Hofmann
Julian Hofmann
PSPhilipp Spatz
Philipp Spatz
RWRasmus Walther
Rasmus Walther
MGMarcus Gutmann
Marcus Gutmann
TMTangui Maurice
Tangui Maurice
MDMichael Decker
Michael Decker
Flavonoids are polyphenolic natural products and have shown significant potential as disease‐modifying agents against neurodegenerative disorders like Alzheimer's disease (AD), with activities even in vivo. Hybridization of the natural products taxifolin and silibinin with cinnamic acid led to an overadditive effect of these compounds in several phenotypic screening assays related to neurodegeneration and AD. Therefore, we have exchanged the flavonoid part of the hybrids with different flavonoids, which show higher efficacy than taxifolin or silibinin, to improve the activity of the respective hybrids. Chemical connection between the flavonoid and cinnamic acid was realized by an amide instead of a labile ester bond to improve stability towards hydrolysis. To investigate the influence of a double bond at the C‐ring of the flavonoid, the dehydro analogues of the respective hybrids were also synthesized. All compounds obtained show neuroprotection against oxytosis, ferroptosis and ATP‐depletion, respectively, in the murine hippocampal cell line HT22. Interestingly, the taxifolin and the quercetin derivatives are the most active compounds, whereby the quercetin derivate shows even more pronounced activity than the taxifolin one in all assays applied. As aimed for, no hydrolysis product was found in cellular uptake experiments after 4 h whereas different metabolites were detected. Furthermore, the quercetin‐cinnamic acid amide showed pronounced activity in an in vivo AD mouse model at a remarkably low dose of 0.3 mg/kg.

Verified
Journal Article
Open access
PDF file
SAStephan Altmann
Stephan Altmann
JMJuergen Mut
Juergen Mut
NWNatalia Wolf
Natalia Wolf
JMJutta Meißner-Weigl
Jutta Meißner-Weigl
Maximilian RudertMaximilian Rudert
Maximilian Rudert
RERegina Ebert
Regina Ebert
Metabolic glycoengineering enables a directed modification of cell surfaces by introducing target molecules to surface proteins displaying new features. Biochemical pathways involving glycans differ in dependence on the cell type; therefore, this technique should be tailored for the best results. We characterized metabolic glycoengineering in telomerase-immortalized human mesenchymal stromal cells (hMSC-TERT) as a model for primary hMSC, to investigate its applicability in TERT-modified cell lines. The metabolic incorporation of N-azidoacetylmannosamine (Ac4ManNAz) and N-alkyneacetylmannosamine (Ac4ManNAl) into the glycocalyx as a first step in the glycoengineering process revealed no adverse effects on cell viability or gene expression, and the in vitro multipotency (osteogenic and adipogenic differentiation potential) was maintained under these adapted culture conditions. In the second step, glycoengineered cells were modified with fluorescent dyes using Cu-mediated click chemistry. In these analyses, the two mannose derivatives showed superior incorporation efficiencies compared to glucose and galactose isomers. In time-dependent experiments, the incorporation of Ac4ManNAz was detectable for up to six days while Ac4ManNAl-derived metabolites were absent after two days. Taken together, these findings demonstrate the successful metabolic glycoengineering of immortalized hMSC resulting in transient cell surface modifications, and thus present a useful model to address different scientific questions regarding glycosylation processes in skeletal precursors.

2 December 2019 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
TLTessa Lühmann
Tessa Lühmann
MGMarcus Gutmann
Marcus Gutmann
AMAlessandra Moscaroli
Alessandra Moscaroli
MRMartina Raschig
Martina Raschig
MBMartin Behe
Martin Behe
LMLorenz Meinel
Lorenz Meinel

9 June 2023 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
AWAlena Maria Wolkersdorfer
Alena Maria Wolkersdorfer
IJIsabelle Jugovic
Isabelle Jugovic
LSLena Scheller
Lena Scheller
MGMarcus Gutmann
Marcus Gutmann
LHLukas Hahn
Lukas Hahn
LMLorenz Meinel
Lorenz Meinel

6 May 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
MBMatthias Beudert
Matthias Beudert
LHLukas Hahn
Lukas Hahn
AHAnselm H.C. Horn
Anselm H.C. Horn
NHNiklas Hauptstein
Niklas Hauptstein
HSHeinrich Sticht
Heinrich Sticht
TLTessa Lühmann
Tessa Lühmann